Jordyn Sava is an assistant editor for Targeted Oncology.
START-001 Study of STAR0602 Doses First Patient With PD-1 Refractory Solid TumorsJanuary 31st 2023
The START-001 trial will administer STAR0602 to patients with PD-1 refractory advanced solid tumors in order to evaluate the safety, tolerability, and preliminary clinical activity of the agent as a monotherapy.
Follow-Up of Lenvatinib/Pembrolizumab Elicits Efficacy in Endometrial CancerJanuary 30th 2023
According to a follow-up analysis of the phase 1b/2 study 111/KEYNOTE-146, lenvatinib/pembrolizumab continued to show tumor responses, overall survival, and progression-free survival benefits in endometrial cancer.
China’s NMPA to Review NDA of Zorifertinib for EGFR-Mutated NSCLC With CNS MetastasesJanuary 30th 2023
The phase 2/3 EVEREST study of zorifertinib for patients with advanced EGFR-mutated non–small cell lung cancer with central nervous system metastases elicited significant efficacy and comparable safety to other tyrosine kinase inhibitors in this indication.
FDA Okays Guardant360 Test as CDx for Elacestrant in ESR1-mutated Breast CancerJanuary 30th 2023
The Guardant360 CDx, which will identify patients with advanced or metastatic breast cancer who have ESR1 mutations and may benefit from elacestrant, is the fifth test to be approved by the FDA and first for patients with breast cancer.
Pembrolizumab Added to Gemcitabine/Cisplatin Improves OS in Biliary Tract CancerJanuary 26th 2023
According to topline findings of the phase 3 KEYNOTE-966 trial, pembrolizumab in combination with gemcitabine and cisplatin led to an improvement in overall survival for patients with biliary tract cancer.
Survivorship and Quality-of-Life Play Important Roles for Patients With Thyroid CancerJanuary 24th 2023
In an interview with Targeted Oncology, Melanie Goldfarb, MD, MSc, FACS, FACE, highlighted the importance of long-term survivorship care and the quality-of-life aspects of patients with thyroid cancer.
Phase 2b/3 MO-TRANS Trial of Mocravimod Enrolls First Patients With AMLJanuary 23rd 2023
After the FDA cleared an investigational new drug application for mocravimod in April 2022, the first patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant have been enrolled in a phase 2b/3 study of the agent.
Lenvatinib Elicits Survival Benefit After Progression on Immunotherapy in HCCJanuary 20th 2023
Patients with advanced hepatocellular carcinoma who were treated with lenvatinib following progression on immunotherapy had a median overall survival of 12.8 months and progression-free survival of 3.7 months.
Ponatinib/Blinatumomab Combo Shows Promising Efficacy and Safety in Ph+ ALLJanuary 20th 2023
Phase 2 study shows ponatinib and blinatumomab to represent a promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.
FDA Grants Orphan Drug Designation to LNS8801 for Metastatic Cutaneous MelanomaJanuary 19th 2023
LNS8801 has proven to be safe, well-tolerated, and demonstrated clinical benefit in patients with advanced cancers. Now, the FDA has granted the agent orphan drug designation for metastatic cutaneous melanoma.
RenovoTAMP Supports Gemcitabine Delivery and Decreases AEs in Pancreatic CancerJanuary 19th 2023
A substudy of the TIGeR-PaC trial showed that treatment with RenovoTAMP may increase local gemcitabine delivery and decrease the debilitating adverse events associated with intravenous administration in pancreatic cancer.
CMG901 Demonstrates Favorable Safety/Tolerability in Advanced Solid TumorsJanuary 18th 2023
Preliminary data from the KYM901 trial of CMG901 revealed promising safety findings for patients with solid tumors. Full data will be presented at the upcoming 2023 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology.
FDA Accepts IND for HT-001 for EGFRi-Associated Rash and Skin DisordersJanuary 17th 2023
Based on the acceptance of its investigational new drug application by the FDA, the safety and tolerability of HT-001 will be evaluated in the phase 2a CLEER of patients with rash and skin disorders associated with EGFR inhibitor therapy.